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The mineralocorticoid receptor (MR) antagonists PF-03882845 and eplerenone
were evaluated for renal protection against aldosterone-mediated renal disease in
uninephrectomized Sprague-Dawley (SD) rats maintained on a high salt diet and receiving
aldosterone by osmotic mini-pump for 27 days. Serum K+ and the urinary albumin to
creatinine ratio (UACR) were assessed following 14 and 27 days of treatment. Aldosterone
induced renal fibrosis as evidenced by increases in UACR, collagen IV staining in kidney
cortex, and expression of pro-fibrotic genes relative to sham-operated controls not
receiving aldosterone. While both PF-03882845 and eplerenone elevated serum K+ levels
with similar potencies, PF-03882845 was more potent than eplerenone in suppressing the
rise in UACR. PF-03882845 prevented the increase in collagen IV staining at 5, 15 and
50mg/kg BID while eplerenone was effective only at the highest dose tested (450mg/kg
BID). All doses of PF-03882845 suppressed aldosterone-induced increases in collagen
IV, transforming growth factor-β1 (Tgf-β1), interleukin-6 (Il-6), intermolecular adhesion
molecule-1 (Icam-1) and osteopontin gene expression in kidney while eplerenone was
only effective at the highest dose. The therapeutic index (TI), calculated as the ratio of the
EC50 for increasing serum K+ to the EC50 for UACR lowering, was 83.8 for PF-03882845
and 1.47 for eplerenone. Thus, the TI of PF-03882845 against hyperkalemia was 57-fold
superior to that of eplerenone indicating that PF-03882845 may present significantly less
risk for hyperkalemia compared to eplerenone.
Keywords: urinary albumin to creatinine ratio, UACR, nephropathy, albuminuria, hyperkalemia, mineralocorticoid
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INTRODUCTION
Mounting clinical evidence suggests a key role for aldosterone
in the progression of nephropathy. Inhibitors of the renin-
angiotensin-aldosterone system (RAAS), such as angiotensin
receptor blockers (ARB) and angiotensin-converting enzyme
inhibitors (ACEI) have been demonstrated to delay the onset of
macroalbuminuria or frank nephropathy in diabetics (Brenner
et al., 2001; Lewis et al., 2001; Parving et al., 2001; Remuzzi et al.,
2002; Ruggenenti et al., 2004). Nonetheless, a significant propor-
tion of patients continue to progress to macroalbuminuria and
overt nephropathy (Parving et al., 2001; Ruggenenti et al., 2004).
Many patients on ACEI or ARB treatment exhibit “aldosterone
escape,” whereby the initial response of decreased aldosterone
and urinary albumin to creatinine ratio (UACR) is followed by a
rebound of aldosterone and reversion of UACR to pre-treatment
levels (Lijnen et al., 1982; Pitt, 1995). The mineralocorticoid
receptor (MR) antagonist spironolactone effectively reduced
UACR in diabetic nephropathy patients exhibiting “aldosterone
escape” while on ACEI therapy (Sato et al., 2003). Moreover,
eplerenone, another marketed MR antagonist, decreased UACR
in type 2 diabetics with mild to moderate nephropathy to a
greater extent than that achieved with ACEI treatment alone,
and independently of changes in blood pressure (Epstein, 2006;
Epstein et al., 2006). However, inhibition of the RAAS with ACEI,
ARB, direct renin inhibitors (DRI) or MR antagonists especially
in dual or triple combination, increased the risk of hyperkalemia
in patients with heart failure (HF), or chronic kidney disease
(McMahon, 2001; Sica, 2002; Palmer, 2004; Weir and Rolfe,
2010).
Aldosterone regulates Na+ and K+ balance and hence extra-
cellular fluid volume and blood pressure (Levy et al., 2004;
Muldowney et al., 2009). Under conditions of low blood vol-
ume or reduced renal perfusion, plasma angiotensin II (angII)
and K+ levels increase and synergistically stimulate aldosterone
secretion from the adrenals thereby promoting Na+ and water
retention in the proximal tubule and driving sodium-dependent
K+ secretion in the distal tubule of the kidney (Palmer, 2004).
Thus, when renal filtration is severely compromised, as in patients
with chronic kidney disease (CKD), cardiometabolic syndrome or
HF, Na+ reabsorption in the proximal tubule becomes highly effi-
cient. Under these conditions, urinary volume and Na+ delivery
to the distal tubule become rate limiting for Na+-dependent K+
secretion and hyperkalemia may ensue (Palmer, 2004). Plasma
aldosterone is increased in some patients with CKD (Berl et al.,
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1978; Hene et al., 1982), diabetes (Hollenberg et al., 2004), and
metabolic syndrome (Bochud et al., 2006), and plasma aldos-
terone correlates positively with UACR (Bianchi et al., 2005) and
negatively with glomerular filtration rates (GFR) in CKD patients
(Quinkler et al., 2005). However, and given the pivotal role of
aldosterone in regulating K+ excretion, the beneficial UACR low-
ering effect of MR antagonists may be offset by an increased
risk of hyperkalemia. Therefore, a MR antagonist that decreases
UACR without increasing the risk of hyperkalemia would be
highly desirable for the treatment and prevention of diabetic
nephropathy.
PF-03882845 is a selective and potent non-steroidal MR antag-
onist. To determine whether PF-03882845 differentiates from
traditional steroidal MR antagonists, we sought to investigate
the effect of PF-03882845 on UACR and electrolyte balance in
preclinical studies. The concentration effect curves for the pre-
vention of increases in UACR and for elevation of serum K+
were established for PF-03882845 and eplerenone in a rat model
of aldosterone-induced renal damage. Additionally, the effect of
the compounds on urinary Na+/K+ ratio, a surrogate biomarker
for electrolyte disturbances, was investigated. Our data indicate
a larger therapeutic index, calculated as the ratio of the EC50 for
increasing serum K+ or urinary Na+/K+ to the EC50 for UACR
lowering, for PF-03882845 compared to eplerenone.
MATERIALS AND METHODS
All procedures were conducted in accordance with Institutional
Animal Care and Use Committee (IACUC) guidelines and regu-
lations at Pfizer Inc (Groton, CT).
SELECTIVITY AND POTENCY OF PF-03882845 AND EPLERENONE
Huh7 cells were transiently transfected with a luciferase reporter
gene under the control of a Gal4 response element (Gal4-RE-luc)
and a plasmid containing the Gal4 DNA binding domain fused
to MR ligand binding domain (Gal4-MR-LBD). Transfected cells
were treated for 24 h with the EC80 concentration of activating
ligand in the presence or absence of PF-03882845 or eplerenone
in serum free medium. Luciferase activity was measured and the
IC50 determined for each compound.
EFFECT OF CHRONIC ADMINISTRATION OF EPLERENONE AND
PF-03882845 ON ALDOSTERONE-MEDIATED RENAL INJURY
Study A
Fifty five male uninephrectomized Sprague Dawley (SD) rats
(Charles River, MA) were singly housed and provided food
and water ad-libitum. Following an acclimation period, base-
line 24 h urine samples were collected and analyzed for albumin
and creatinine measurement. Baseline blood was taken by tail
bleed for measurement of serum K+. Rats were then random-
ized into 5 groups. Four groups of rats (n = 11 per group) were
implanted subcutaneously (SC) with Alzet mini-pumps (Alzet,
Cupertino, CA) to deliver 2.5μL/h aldosterone (0.75μg/h) in
0.01% dimethylsulfoxide (DMSO) under isoflurane anesthesia.
One group was sham operated (Veh Sham, n = 11). Immediately
post-surgery, all rats were switched to a 6% high salt diet (Teklad
TD.90230) and water containing 0.3% KCl ad-libitum. The fol-
lowing day, treatment with eplerenone was initiated in the 4
groups of rats that were implanted with aldosterone mini-pumps.
Rats received either vehicle (Veh Aldo), or one of 3 doses of
eplerenone: 15, 50, or 450mg/kg BID by oral gavage. The sham-
operated group also received vehicle (Veh Sham). Dosing was
performed at 6 am and 4 pm for a duration of 27 days. Eplerenone
was dissolved in vehicle comprised of 0.5%methyl cellulose, 0.1%
polysorbate 80 in water.
Study B
For study B the same protocol as study A was used, but PF-
03882845 was administered in lieu of eplerenone at doses of 5,
15, and 50mg/kg BID by oral gavage. PF-03882845 was dissolved
in vehicle comprised of 0.5% methyl cellulose, 0.1% polysorbate
80 in water.
URINE COLLECTION
Twenty-four hours urine samples were collected at baseline, on
Days 14 and 25 of treatment. Urine volume was recorded and
samples were utilized for creatinine and albumin concentrations.
PLASMA/SERUM COLLECTION
Rats were bled at baseline for plasma K+ measurement. Following
the first dose of the respective compounds, rats were bled at 1, 2,
4, 7 h for drug levels measurements. On Day 14 of treatment, rats
were bled at 7 h post the first dose of the day for plasma drug levels
and serum K+ measurements. Additionally on Day 26, rats were
bled at 1, 2, 4, 7 h post-dose for plasma drug levels measurement.
On Day 27 (at necropsy, ∼16 h post final dose), rats were bled for
measurement of serumK+ and plasma drug levels measurements.
TISSUE COLLECTION
On Day 27 rats were euthanized with CO2, in accordance with
IACUC guidelines and regulations at Pfizer Inc (Groton, CT).
Kidney was removed, and weighed. A section of kidney was fixed
in 10% formalin for histological analysis and a second portion
of kidney (200mg) was stored in a RNA stabilization reagent
(RNAlater, Qiagen) for gene expression analysis.
HISTOLOGY
Kidney sections were stained with a rabbit anti-collagen-IV anti-
body (Thermo Scientific) and detected with an anti-rabbit anti-
body conjugated to horseradish peroxidase (HRP). Slides were
counterstained with hematoxylin. Data were expressed as percent
collagen IV staining of the kidney cortex.
RT-PCR
Kidney samples (∼30 mg) were removed from RNAlater and
homogenized in 700μL of buffer RLT for RNA purification using
an RNeasy Mini Kit (Qiagen) with on-column DNase treat-
ment. Purified RNA was quantitated by NanoDrop. Samples
(20 ng) were analyzed by RT-PCR to assess relative mRNA expres-
sion of Collagen-IV (Col4a1), osteopontin (Spp1), interleukin-6
(Il-6), intercellular adhesion molecule 1 (Icam-1), monocyte
chemoattractant protein-1 (Mcp-1) and transforming growth
factor β-1 (Tgf-β1) using gene expression assays (Applied
Biosystems), RNA to Ct Kit (Applied Biosystems) and the SDS-
7900HT (Applied Biosystems). Expression data were normalized
to mRNA expression of the endogenous control hypoxanthine
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phosphoribosyltransferase 1 (Hprt1). Data were expressed as rel-
ative quantitation (RQ) units using Veh Sham animal No. 2 as
comparator (ie RQ equal to “1”).
BIOMARKER MEASUREMENTS
Serum K+, urinary albumin and creatinine were measured using
the Siemens Advia 2400 Chemistry Analyzer and reagents from
Siemens Healthcare Diagnostics (Washington, DC). UACR was
calculated as the ratio of urinary albumin concentration to cre-
atinine concentration. Plasma osteopontin was measured on day
27 samples using an enzyme immunoadsorbent assay (Enzo Life
Sciences, Inc., Farmingdale NY).
COMPOUND EXPOSURE
Plasma was analyzed for eplerenone or PF-03882845 using a
non-GLP LC/MS/MS method. All calculations were performed
in Watson LIMS (v7.2, Thermo, Inc, Philadelphia, PA) and indi-
vidual data were used in all pharmacokinetic analyses. The area
under the plasma concentration-time curve (AUC(0-last)) was
estimated using the linear trapezoidal rule.
PHARMACOKINETIC/PHARMACODYNAMIC (PK-PD) MODELING FOR
STUDY A AND STUDY B
Population PK-PD modeling was conducted in NONMEM (ver-
sion VI 2.0; GloboMax LLC. Hanover, MD). Analysis was
conducted in a piece-wise manner whereby individual pharma-
cokinetic parameters estimated for each animal in step 1 were
fixed during estimation of pharmacodynamic parameters in the
second step.
The pharmacokinetics of eplerenone and PF-03882845 were
characterized with one and two compartmental models, respec-
tively. In both cases first order absorption and elimination was
assumed. Decreases in exposure upon multiple dosing for both
compounds were characterized assuming that clearance was
induced between Days 1 and 7 and remained constant thereafter.
Population variance on the rate of absorption, elimination and
volume of distribution were assumed in order to provide the best
possible description of exposure in individual animals. Individual
pharmacokinetic parameter estimates were carried forward in
modeling the PK-PD relationship to UACR and serum K+.
Increases in UACR in vehicle controls were modeled with an
indirect response model where the initial value (i.e., UACR at
the start of the study) represents a non-steady state condition
that varies between individual rats. Drug effect was parameter-
ized such that the increase in UACR was inhibited via an indirect
response Imax model (Equation 1). Both eplerenone and PF-
03882845 PK-PD data were modeled simultaneously. The Imax,
Kin, and Kout parameters were assumed to be drug independent
and only the IC50 parameter was assumed to be drug dependent.
dUACR
dt
= Kin ×
[
1 − Imax × C
C + IC50
]
− Kout × UACR (1)
For modeling purposes, serumK+ data were transformed accord-
ing to Equation 2. This formula allows for the calculation of
drug-induced changes in serum K+ (from baseline), which are
above and beyond that measured in the vehicle group. T × T and
T× 0 represent themeasured serumK+ in each drug treated indi-
vidual at times equal to “T” and 0, respectively. VehT and Veh0
represent the mean measured serum K+ in the vehicle group at
times equal to “T” and 0, respectively.
 serumK = (T × T − T × 0) − (VehT − Veh0) (2)
The relationship between drug exposure and  serum K+ was
modeled using a modified indirect response model whereby drug
creates a concentration-dependent input rate (Equation 3). Both
eplerenone and PF-03882845 PK-PD data were modeled simul-
taneously. The Kin, max, and Kout parameters were assumed to be
drug independent and only the EC50 parameter was assumed to
be drug dependent.
d serumK
dt
= Kin − Kout ×  serumK; where Kin
= Kin, max × C
C + EC50 (3)
ACUTE EFFECT OF MR ANTAGONISTS ON URINARY NA+/K+ RATIO
Male, carotid artery cannulated, Sprague Dawley (SD) rats
between 11 and 12 weeks of age were obtained (Charles River,
MA), singly housed and acclimated in metabolic chambers for
one week prior to the start of the experiment. Water and food
(Purina 5001 pellets) were provided ad-libitum throughout the
study. In one study, rats were randomly assigned to receive either
vehicle (0.5% methyl cellulose, 0.1% polysorbate 80) alone or
eplerenone at one of 3 doses: 5, 30 or 300mg/kg. In a second
study, rats were randomly assigned to receive either vehicle (0.5%
methyl cellulose, 0.1% polysorbate 80) or PF-03882845 at one of
3 doses: 3, 10 and 30mg/kg. On the evening prior to treatment
administration, baseline urine was collected from 4 pm until 8 am
on the day of treatment. Animals were then orally gavaged with
their respective treatments at 8 am and urine collected at inter-
vals of 0–2, 2–4, and 4–7 h post dose. After collection, urine was
stored at−80◦C until analyzed. Baseline blood was collected from
carotid artery cannulas prior to dosing, and at 1, 2, 4, and 7 h
post dose. Samples were centrifuged and plasma was collected
and stored at −80◦C for compound exposure measurements
using the methodology described above. Urine sodium and K+
were measured using the Siemens Advia 2400 Chemistry Analyzer
with reagents from Siemens Healthcare Diagnostics. Data were
expressed as urinary Na+/K+ ratio.
PK MODELING FOR EPLERENONE
A two compartment distribution model with zero order absorp-
tion was used (1 h duration = observed Tmax). Clearance (CL)
was estimated as a function of dose:
CL = (THETA(1)∗(30/DOSE)∗∗PWR)∗EXP(ETA(1))
where Theta(1) is CL at 30mg/kg, and PWR is a power function
allowing non-linear change in CL with dose. Conditional esti-
mates of CL, V1, and Q were obtained. A proportional residual
error model was used.
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PK MODELING FOR PF-03882845
A one compartment distribution model with first order absorp-
tion was used. Conditional estimates of KA, CL, and V1 were
obtained. A proportional residual error model was used.
PK/PD MODELING OF URINARY Na+/K+
A two compartment linear model with first order absorption was
used for both drugs. Conditional PK parameter estimates were
read in with the input data. For PF-03882845, drug was dosed
into compartment 1 (depot); Q was fixed to 0 and V2 was fixed
to 1. For eplerenone, KA was fixed to 1 and drug was “infused”
into compartment 2 over 1 h. The PD endpoint was the “dou-
ble delta” in urinary Na+/K+ ratio (measured at the midpoint
of the urine collection interval). Mean vehicle Na+/K+ ratio at
time = 0 (Veh0) and at each urine collection interval (VehT)
was estimated using vehicle data from both drug studies com-
bined. Individual animal Na+/K+ ratio observed at time = 0
(T × 0) and at the midpoint of collection intervals (T × T) were
used to calculate the “double delta” change in Na+/K+ ratio as
follows:
DDresponse = (TxT − Tx0) − (VehT − Veh0)
Using this approach each animal’s time zero response = 0.
STATISTICAL ANALYSES
UACR and serum K+ data were analyzed using a mixed ANOVA
model accounting for repeated measures where treatment group,
days post operation and treatment day interaction effect were
introduced as a fixed factor whereas the animal factor was con-
sidered as a random effect nested in the treatment factor. The
baseline value for each animal was introduced as a covariate. The
primary comparisons were vehicle sham group vs. the other four
groups and the vehicle aldosterone group vs. treatment groups. A
two-sided 5% test was conducted.
For Study A and Study B, kidney gene expression data, colla-
gen IV staining data and plasma osteopontin data were analyzed
with a One-Way ANOVA and a Tukey post test using GraphPad
Prism 5. When unequal variances were observed, data were log-
transformed prior to analysis. The primary comparisons were
vehicle sham group vs. the other four groups and the vehicle
aldosterone group vs. treatment groups.
RESULTS
POTENCY OF PF-03882845 AND EPLERENONE
PF-03882845 exhibited a greater potency compared to eplerenone
in a serum free functional reporter assay utilizing the human
MR ligand binding domain [PF-03882845 geometric mean
IC50 = 0.755 nM (90% confidence interval: 0.501–1.11 nM;
n = 6), eplerenone IC50 = 109 nM (90% confidence interval:
79.3–150 nM; n = 6)].
EFFECT OF EPLERENONE AND PF-03882845 ON UACR AND SERUM K+
Baseline UACR levels were not different amongst groups.
Aldosterone infusion increased UACR levels relative to the vehi-
cle sham group in both Study A and Study B by Day 14
(Figures 1A, 2A, respectively). This effect was more pronounced
FIGURE 1 | Effect of eplerenone on UACR on day 14 (A) and day 26 (B).
Data are represented as mean ± standard error of the mean. See Materials
and Methods for statistical analysis. ∗ Indicates a significant difference from
the vehicle sham (Veh Sham) group; #Indicates a significant difference from
the vehicle + aldosterone (Veh Aldo) group.
by Day 26 (Figures 1B, 2B, respectively). The highest dose of
eplerenone (450mg/kg BID) prevented the increase on Days
14 and 26 of treatment (Figures 1A,B) while all doses of
PF-03882845 were efficacious in blunting UACR elevations
(Figures 2A,B). Aldosterone decreased serum K+ on Days 14 and
26 in Study A (Figures 3A,B) but only on Day 26 in Study B
(Figures 4A,B). By Day 26, eplerenone prevented the aldosterone-
induced decrease in serum K+ at the doses of 50mg/kg and
450mg/kg BID (Figure 3B). A similar effect was observed
with PF-03882845 at the highest dose tested (50mg/kg BID;
Figure 4).
PK-PD MODELING OF UACR AND SERUM K+
Model estimated values of the EC50 for UACR and for serum
K+ are depicted in Figure 5 and Table 1. Eplerenone and PF-
03882845 resulted in overlapping concentration effect curves for
serum K+ (Figure 5B) and the derived EC50 values were not
significantly different (Table 1). By contrast, PF-03882845 was
more potent than eplerenone in preventing the rise in UACR as
observed in the modeled concentration-effect curves (Figure 5A).
The resulting EC50 was 64-fold lower compared to eplerenone
(Figure 5A and Table 1). The therapeutic index (TI), calculated
as the ratio of EC50 for increasing serum K+ to the EC50 for sup-
pressing UACR, was 1.47 for eplerenone and 84 for PF-03882845
(Table 1).
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FIGURE 2 | Effect of PF-03882845 on UACR on day 14 (A) and day
26 (B). Data are represented as mean ± standard error of the mean. See
Materials and Methods for statistical analysis. ∗ Indicates a significant
difference from the vehicle sham (Veh Sham) group; #Indicates a significant
difference from the vehicle + aldosterone (Veh Aldo) group.
EFFECT OF PF-03882845 AND EPLERENONE ON COLLAGEN IV STAINING
IN KIDNEY
Continuous infusion with aldosterone significantly increased col-
lagen IV staining in kidney cortex (Figures 6B,F) vs. the vehicle
sham group (Figures 6A,E) in Study A and Study B, respectively.
Eplerenone prevented the increase in collagen IV staining at the
450mg/kg BID dose only (Figures 6C,D,J) while all three doses of
PF-03882845 were efficacious (Figures 6G–I, 6K).
EFFECT OF PF-03882845 AND EPLERENONE ON GENE EXPRESSION IN
KIDNEY
In studies A and B, aldosterone significantly increased mRNA
expression of collagen 4a1, transforming growth factor β-1
(Tgf-β1), interleukin-6 (Il-6), intercellular adhesion molecule-
1 (Icam-1), monocyte chemoattractant protein-1 (Mcp-1), and
osteopontin (Spp1) in the kidney on Day 27. This was prevented
by PF-03882845 at all doses tested (Table 2), while eplerenone
prevented the rise in these genes only at the highest dose tested
(4.0mg/kg BID) (Table 3).
EFFECT OF PF-03882845 AND EPLERENONE ON PLASMA OSTEOPONTIN
Aldosterone increased plasma osteopontin levels in Study A (vehi-
cle: 93.6 ± 16.4 ng/ml; vehicle + aldosterone: 345 ± 205 ng/ml
(mean ± SEM)) and this effect was blunted by eplerenone at the
450mg/kg BID dose (62.2 ± 7.98 ng/ml), while the doses of 15
FIGURE 3 | Effect of eplerenone on serum K+ on day 14 (A) and day
26 (B). Data are represented as mean ± standard error of the mean. See
Materials and Methods for statistical analysis. ∗Indicates a significant
difference from the vehicle sham (Veh Sham) group; # Indicates a
significant difference from the vehicle + aldosterone (Veh Aldo) group.
or 50mg/kg BID were not different from the vehicle + aldos-
terone group (eplerenone 15mg/kg BID: 204 ± 35.1; eplerenone
50mg/kg BID: 234 ± 85.6 ng/ml). In study B, aldosterone
increased plasma osteopontin levels (vehicle: 87.3 ± 13.9 ng/ml;
vehicle + aldosterone: 494 ± 90.1 ng/ml). This effect was sup-
pressed at all doses of PF-03882845 (PF-03882845.5mg/kg BID:
108 ± 13.5, 15mg/kg BID: 77.1 ± 15.7 and 50mg/kg BID: 82.4 ±
17.0 ng/ml, respectively).
ACUTE EFFECT OF PF-03882845 AND EPLERENONE ON URINARY
NA+/K+ RATIO
Urinary Na+/K+ ratio was assessed in SD rats following single
doses of PF-03882845 or eplerenone. Concentration-effect curves
were generated using an indirect response model. In agreement
with the chronic effects of these compounds on serum K+ levels,
the EC50 values for the acute effect on urinaryNa+/K+ ratios were
not different when corrected for the respective free fraction and
in vitro potency (PF-03882845 (mean [95% confidence interval]:
3.10 [1.58–4.62]) and eplerenone (5.92 [2.22–9.63]) (Figure 7).
DISCUSSION
We investigated whether PF-03882845, a novel non-steroidal MR
antagonist, differentiates from traditional steroidal MR antago-
nists, such as eplerenone. Our findings indicate that PF-03882845
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FIGURE 4 | Effect of PF-03882845 on serum K+ on day 14 (A) and day
26 (B). Data are represented as mean ± standard error of the mean. See
Materials and Methods for statistical analysis. ∗Indicates a significant
difference from the vehicle sham (Veh Sham) group; #Indicates a significant
difference from the vehicle + aldosterone (Veh Aldo) group.
exhibits a greater TI, calculated as the ratio of the EC50 for
increasing serum K+ to the EC50 for UACR lowering, compared
to eplerenone. Thus, our results support the development of PF-
03882845 for the treatment of diabetic nephropathy, a condition
in which the patient is particularly at risk for hyperkalemia.
Aldosterone binding to the MR mediates sodium and water
retention in exchange for K+ secretion in the renal tubules.
These effects appear to be downstream of the serum- and
glucocorticoid-inducible kinase-1 (SGK1) (Lang et al., 2006;
Terada et al., 2008). Indeed, aldosterone has been demonstrated to
stimulate Sgk1 mRNA expression (Naray-Fejes-Toth et al., 1999)
and phosphorylation (Flores et al., 2005) in cortical collecting
duct cells. Activated SGK1 inhibits turnover of the epithelial
sodium channel (ENaC) thereby enhancing ENaC abundance
at the plasma membrane (Butterworth et al., 2009) via phos-
phorylation and inhibition of the ubiquitinase Nedd4-2 which
marks ENaC for proteasomal degradation (Flores et al., 2005).
Sodium transport is also regulated by the With-No-K (lysine)
kinase (WNK) family of kinases amongst which WNK4 has
been demonstrated to phosphorylate and inhibit ENaC and the
Na+ and Cl− cotransporter (NCC) (Hoorn et al., 2009). In
turn, WNK4 is phosphorylated and inhibited by SGK1 and by
the “long form”-WNK1 (L-WNK1). Thus, aldosterone increases
FIGURE 5 | PK-PD modeling of UACR and serum potassium.
Concentration-effect curves of eplerenone (gray lines) and PF-03882845
(black lines) for UACR (A) and serum K+ (B) following 27 days of
treatment. Dashed lines indicate the 95% upper and lower confidence
intervals. Data were modeled using an indirect response model. A
double delta equation was used to express the pharmacodynamic
response for serum K+.
Na+ retention via SGK1 mediated phosphorylation/inhibition of
WNK4, thereby relieving inhibition of ENaC and NCC (Hoorn
et al., 2009; Vallon et al., 2009).
Aldosterone modulates K+ secretion via SGK1 upregula-
tion of the renal outer medullary potassium (ROMK) chan-
nels in the thick ascending limb of Henle’s loop, the distal
tubule and in cortical collecting duct cells. L-WNK1 and WNK4
downregulate ROMK by stimulating clathrin-dependent endo-
cytosis and this is abrogated by SGK1 mediated phosphoryla-
tion of Wnk4 (Welling and Ho, 2009). In addition to effects
on ENaC and ROMK, aldosterone increases K+ secretion in
exchange for sodium uptake via the basolateral Na+/K+ ATPase
(Djelidi et al., 2001).
In the present study, aldosterone treatment of uninephrec-
tomized rats depressed serum K+ levels as anticipated. In con-
trast, treatment with the MR antagonists blunted this effect, likely
through preventing aldosterone-induction of ENaC, ROMK and
the Na+/K+ ATPase. PK-PD modeling demonstrated that PF-
03882845 and eplerenone were equipotent for increasing serum
K+ levels relative to the vehicle + aldosterone group and for
increasing the urinary Na+/K+ ratio following single doses in
normal SD rats. Effects of MR antagonists on urinary Na+/K+
ratio have been well-characterized in rodents as well as humans
Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery October 2013 | Volume 4 | Article 115 | 6
Orena et al. MR antagonism in nephropathy
Table 1 | Chronic effect of PF-03882845 and eplerenone on UACR and serum K+.
Compound Endpoint EC50 nM 95% CI 95% CI fEC50 nM(corrected for fEC50/in vitro TI (95%
(Total conc) lower limit upper limit for protein binding)a potencyb CI)c
PF-03882845 Serum K+ 874 75.5 1671 3.32 4.43 84.0
UACR 10.4 2.36 18.5 0.0395 0.0527 (4.1–710)
Eplerenone Serum K+ 988 134 1843 672 6.16 1.47
UACR 671 411 932 456 4.19 (0.14–4.5)
Data expressed as EC50 with 95% confidence interval (CI).
afEC50: EC50 multiplied by fraction unbound: PF-03882845: 0.0038; Eplerenone: 0.68.
bIn vitro potency: PF-03882845: 0.75 nM; Eplerenone: 109 nM.
cTherapeutic index (TI) calculated as the ratio of “EC50/in vitro potency” for serum K+ to “EC50/in vitro potency” for UACR.
FIGURE 6 | Representative images of collagen IV immunohistochemical
localization in kidney cortex. Study A, vehicle sham (A), vehicle +
aldosterone (B), 50mg/kg BID eplerenone (C), and 450mg/kg BID
eplerenone (D), groups following 27 days of treatment; and Study B, kidney
cortex from sham vehicle (E), vehicle + aldosterone (F), 5mg/kg BID
PF-03882845 (G), 15mg/kg BID PF-03882845 (H), and 50mg/kg BID
PF-03882845 (I) following 27 days of treatment. Data expressed as %
collagen IV staining in kidney cortex and represented as mean ± standard
error of the mean: Study A (J) and Study B (K). See Materials and Methods
for statistical analysis. ∗Indicates a significant difference from the vehicle
sham (Veh Sham) group; #Indicates a significant difference from the vehicle
+ aldosterone (Veh Aldo) group.
(McInnes et al., 1982). Early on, Kagawa demonstrated block-
ade of mineralocorticoid activity in adrenalectomized rats by
measuring urinary Na+/K+ ratio (Kagawa, 1960). This method
was further simplified by Brandish et al. who revealed simi-
lar findings in rats with intact adrenal glands (Brandish et al.,
2008). We have previously demonstrated translatability of this
biomarker from rat to humans using preclinical and clinical
data generated with eplerenone (Eudy et al., 2011). Our present
findings extend these results by demonstrating similar concen-
tration effect curves for urinary Na+/K+ ratio generated in
normal SD rats following single doses of MR antagonists, and
for serum K+ in an animal model of nephropathy following
chronic exposure to the compounds. Thus, urinary Na+/K+
ratio in a healthy state appears to be a useful biomarker for
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Table 2 | Effect of PF-03882845 on relative gene expression in kidney on day 27.
PF-03882845 Veh sham Veh aldo PF-038828455mg/kg BID PF-0388284515mg/kg BID PF-0388284550mg/kg BID
Tgf-1β 0.95 ± 0.039 1.7 ± 0.14* 1.0 ± 0.088∧ 0.93 ± 0.092∧ 0.89 ± 0.071∧
Col4a1 0.92 ± 0.051 1.5 ± 0.11* 1.0 ± 0.099∧ 1.1 ± 0.12∧ 0.94 ± 0.059∧
Il-6 1.0 ± 0.14 6.6 ± 0.68* 1.6 ± 0.29∧ 1.1 ± 0.18∧ 1.2 ± 0.18∧
Icam-1 1.1 ± 0.050 1.8 ± 0.14* 1.1 ± 0.077∧ 1.2 ± 0.12∧ 1.2 ± 0.056∧
Mcp-1 0.96 ± 0.089 1.8 ± 0.26* 0.95 ± 0.082∧ 0.64 ± 0.070∧ 0.76 ± 0.090∧
Spp1 0.92 ± 0.11 11 ± 1.9* 1.3 ± 0.23∧ 0.73 ± 0.081∧ 0.60 ± 0.20∧
Values are mean relative quantitation ± standard error of the mean, n = 8–10/group. One-Way ANOVA with Tukey’s post-hoc analysis was performed. *Significantly
different from vehicle sham (Veh sham); ∧significantly different from vehicle + aldosterone (Veh aldo).
Table 3 | Effect of eplerenone on gene expression in kidney on day 27.
Eplerenone Veh sham Veh aldo Eplerenone15mg/kg BID Eplerenone50mg/kg BID Eplerenone4.0mg/kg BID
Tgf-1β 1.1 ± 0.071 1.9 ± 0.20* 1.7 ± 0.12 1.6 ± 0.20 1.2 ± 0.039∧
Col4a1 1.0 ± 0.050 1.6 ± 0.16* 1.4 ± 0.087* 1.2 ± 0.057 1.1 ± 0.050∧
Il-6 1.1 ± 0.25 6.3 ± 1.5* 5.0 ± 0.89* 5.5 ± 1.4 3.5 ± 1.5
Icam-1 1.2 ± 0.047 1.9 ± 0.18* 1.9 ± 0.20* 1.8 ± 0.25 1.2 ± 0.060∧
Mcp-1 1.1 ± 0.10 2.2 ± 0.25* 2.6 ± 0.56* 2.6 ± 0.54* 1.4 ± 0.26
Spp1 2.0 ± 0.33 46 ± 11* 25 ± 5.3* 30 ± 9.7* 3.2 ± 0.75∧
Values are mean realtive quantitation ± standard error of the mean, n = 10–11/group. One-way ANOVA with Tukey’s post-hoc analysis was performed. *Significantly
different from vehicle sham (Veh sham); ∧Significantly different from vehicle + aldosterone (Veh aldo).
FIGURE 7 | Effect of eplerenone and PF-03882845 on urinary Na+/K+
ratio. SD rats received single doses of 0, 5, 30, or 3.0mg/kg eplerenone or
0, 3, 10, or 30mg/kg PF-03882845 and urinary Na+/K+ was assessed at
0–2, 2–4, and 4–7 h post-dose. Both compounds yielded analogous
concentration-effect curves for urinary Na+/K+. Data were expressed as
free concentration normalized to in vitro IC50 (0.75 nM for PF-03882845 and
109 nM for eplerenone in a serum free assay). Data were modeled using an
indirect response model. Dashed lines indicate the 95% lower and upper
confidence boundary limits.
assessing the risk of hyperkalemia in a renally compromised
condition.
Interestingly, PK-PD modeling revealed that PF-03882845 was
more potent than eplerenone in lowering UACR despite equipo-
tent effects on serum potassium, thereby yielding a 57-fold greater
therapeutic index against hyperkalemia compared to eplerenone.
Albuminuria, a widely used surrogate biomarker of renal damage,
has been previously demonstrated to be decreased by treatment
with MR antagonists in patients with nephropathy (Sato et al.,
2003; Epstein et al., 2006) and rodents with renal impairment
(Blasi et al., 2003), supporting its modulation by aldosterone. Our
results agree with these findings, and further highlight the poten-
tial of PF-03882845 in preventing/reducing renal damage, while
posing less risk for hyperkalemia compared to a traditional MR
antagonist. Concurrent with its effect on UACR, PF-03882845
was more potent than eplerenone in suppressing collagen IV
gene and protein expression in kidney cortex. Collagen IV has
been associated with glomerulosclerosis in experimental mod-
els (Floege et al., 1992; Bergijk et al., 1998; Lee et al., 1998)
and humans (Kim et al., 1991; Tamsma et al., 1994; Esposito
et al., 1996) with kidney disease. Renal biopsies from patients
with diabetic nephropathy indicated a clear increase in α2 type
IV collagen gene and protein in glomeruli compared to controls
(Adler et al., 2000). Importantly, aldosterone has been shown
to stimulate collagen synthesis in rat renal fibroblasts (Nagai
et al., 2005) and aldosterone infusion stimulated collagen III
gene expression as assessed by in situ hybridization (Blasi et al.,
2003). We expand on these findings by demonstrating increases
of collagen IV gene and protein expression in kidney cortex
with aldosterone infusion, and its blunting by the novel MR
antagonist PF-03882845. Furthermore, our data indicate a greater
potency of PF-03882845 compared to eplerenone for suppressing
aldosterone-induced expression of proinflammatory and profi-
brotic genes in the kidney such as Tgf-β, Il-6, Icam-1, Mcp-1
and Spp1. ICAM-1 has been implicated in glomerular inflam-
mation (Riser et al., 2001). Il-6 has been shown to upregulate
MCP-1 in human mesangial cells (Coletta et al., 2000). The latter
was upregulated in urine of patients with diabetic nephropathy
(DN) (Wada et al., 2000) and was decreased by spironolactone
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treatment (Takebayashi et al., 2006) suggesting regulation by the
MR. TGF-β1 has been demonstrated to reduce collagenase pro-
duction thereby leading to accumulation of extracellular matrix
components (Wolf, 2006). Importantly, Tgf-β1 is increased in
plasma of type 2 diabetics (Pfeiffer et al., 1996) and urine of type
2 diabetics with clinical diabetic nephropathy (Bertoluci et al.,
2006) further supporting its role in the pathogenesis of this dis-
ease. In accordance with our findings, aldosterone infusion has
been shown to increase TGF-β1 protein expression in rat kidney
(Juknevicius et al., 2004) and both TGF-β1 and aldosterone inde-
pendently stimulated connective tissue growth factor (CTGF), an
inducer of renal fibroblast growth and synthesis of extracellu-
lar matrix proteins (Yokoi et al., 2001). In the present studies,
aldosterone infusion also resulted in an increased intra-renal gene
expression of osteopontin (Spp1), an extracellular matrix protein,
chemokine and growth factor recently shown to be regulated by
the MR in renal mesangial cells (Gauer et al., 2008). This effect
was prevented more potently by PF-03882845 as compared to
eplerenone. Importantly, plasma levels of osteopontin mirrored
these findings. These results further support a greater potency
of PF-03882845 vs. eplerenone in preventing renal damage as
plasma levels of osteopontin have been shown to correlate with
progression of diabetic nephropathy (Yamaguchi et al., 2004).
While our results clearly indicate a greater potency of PF-
03882845 in reducing UACR compared to eplerenone, leading
to an increased TI against hyperkalemia, mechanisms underlying
these findings are yet to be determined. At least 3 hypothe-
ses may explain the present data. First, PF-03882845 may dif-
ferentially affect coactivator recruitment in different cell types
leading to a greater repression of profibrotic pathways. Second,
a greater uptake of PF-03882845 relative to eplerenone in
cell types involved in filtration and fibrosis such as mesan-
gial cells and/or podocytes compared to epithelial cells that
regulate electrolyte balance could account for these findings.
However, to-date, no evidence of active uptake of PF-03882845
into cells has been demonstrated. Third, the increased potency
of PF-03882845 against fibrosis may be driven through off-
target effects. Recently, aldosterone has been demonstrated
to elicit effects on vascular smooth muscle cells at phys-
iological concentrations through the GPR30 receptor (Gros
et al., 2011). Further work is warranted to elucidate these
findings.
In conclusion, PF-03882845, a novel non-steroidal MR antag-
onist, appears to present less of a risk for hyperkalemia
while maintaining efficacy in preventing renal damage in a
rodent model of nephropathy. Should these results translate
into humans, PF-03882845 may present a safe and efficacious
alternative for the treatment of chronic kidney disease.
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